Bronchitis Research Today is a free monthly online journal that collates and summarizes the latest research about Bronchitis, including details on pulmonary disorders, symptoms, diagnosis, treatment, prevention.

CF-Emerging therapies: Modulation inflammation.

Fayon M,

C.R.C.M. pédiatrique & Centre de Recherche (CEDRE), CHU de Bordeaux-Université Victor Segalen Bordeaux 2, Laboratoire de Physiologie Cellulaire Respiratoire, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France. michael.fayon@chu-bordeaux.fr

Persistent and dysregulated inflammation, combined with an exaggerated host response is a major contributor to CF lung disease. As lung disease progresses, neutrophil accumulation in the airways ensues. Modulation of CF airway inflammation may result in either beneficial or deleterious side effects, resulting in more harm than good. Antibiotics, in particular, macrolides which act as a long-term anti-inflammatory agent with an excellent safety profile, and dornase alpha, are very interesting agents; steroids are not indicated in CF except in very special situations, and other promising agents such as leukotriene modifiers, high-dose N-acetylcysteine, anti-elastase and anti-cytokines require further research. Research should focus on early treatment, before lung damage has occurred.

Published 26 June 2006 in Paediatr Respir Rev, 7: S170-4.
Full-text of this article is available online (may require subscription).

© 2005-2008 Bronchitis Research Today. All Rights Reserved.